Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
(4) - EconoTimes)
SAN DIEGO, Jan. 05, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported a grant under its 2017 Inducement Equity Incentive Plan to Russell Cox, who joined Vital Therapies as its Chief Executive Officer, effective January 3, 2018.
The grant made January 3, 2018 is an award of a nonstatutory stock option to purchase 1,588,832 of Vital Therapies’ common stock. The grant was made outside of Vital Therapies’ current equity plan, but will be subject to terms and conditions generally consistent with those in its 2014 Equity Incentive Plan. The option has a 10-year term and an exercise price that is the same as the closing price of Vital Therapies’ common stock on the grant date. The option grant will vest over four years with 25% of the total shares vesting one year from his start date and 1/48th of the total shares vesting monthly for the next three years subject to his continued service.
The grant was approved by Vital Therapies’ Compensation Committee of the Board of Directors on January 2, 2018. In accordance with NASDAQ Listing Rule 5635(c)(4), the grant was made as an inducement material to entering into an employment relationship with Vital Therapies.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
